Story

New York Yankees in Talks With Apollo for Nearly $3 Billion Financing, Bloomberg Reports

ENTHMSVIIDZHZH-TWJAKOHI
Jul 15, 20261 min read
New York Yankees in Talks With Apollo for Nearly $3 Billion Financing, Bloomberg Reports

Summary

Yankee Global Enterprises, the parent company of the New York Yankees, is reportedly in advanced discussions with Apollo Global Management for a financing package that would value close to $3 billion.

Text size
Background

Yankee Global Enterprises, the parent company of the New York Yankees, is in advanced discussions to secure nearly $3 billion in financing from private capital firm Apollo Global Management Inc., according to a report from Bloomberg News citing people familiar with the matter.

Deal Structure and Purpose

The proposed financing package is being negotiated between the Major League Baseball team's parent company and Apollo's sports investing unit. The deal is expected to consist primarily of debt, with a smaller equity component included, the sources told Bloomberg.

A portion of the capital raised would be used to refinance existing debt held by Yankee Global Enterprises. The remainder of the funds would be allocated toward financing future growth opportunities for the company.

Sample IUX Markets – In-articleAd

Context and Market Implications

Yankee Global Enterprises, controlled by the Steinbrenner family, holds a diverse portfolio of sports assets beyond the iconic baseball team. Its investments include Italian soccer club AC Milan and Major League Soccer's New York City FC.

This potential deal underscores a growing trend of major institutional investors and private equity firms providing sophisticated financing solutions to high-value sports franchises. These teams are increasingly viewed as stable, media-driven assets capable of attracting significant private capital for expansion, operations, and strategic investments.

Read next

More on Stocks
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Stocks

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Sep 20, 2026

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.

Back to latest news

LATEST